Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)

Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Dutton, S, Blazeby, J, Petty, R, Mansoor, W, Thompson, J, Harrison, M, Abbas, H, Dahle-Smith, A, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Harvey, C, Julier, P, Jankowski, J, Midgley, R, Ferry, DR, Grp, C
Formáid:	Journal article
Foilsithe / Cruthaithe:	2013

Míreanna comhchosúla

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
de réir: Dutton, S, et al.
Foilsithe / Cruthaithe: (2014)

Gefitinib and Epidermal Growth Factor Receptor Gene Copy Number Aberrations in Esophageal Cancer
de réir: Petty, R, et al.
Foilsithe / Cruthaithe: (2017)

Gefitinib and EGFR gene copy number aberrations in esophageal cancer
de réir: Petty, RD, et al.
Foilsithe / Cruthaithe: (2017)

Busting the Breast Cancer with AstraZeneca’s Gefitinib
de réir: S. Chemmalar, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
de réir: Shuang Zhao, et al.
Foilsithe / Cruthaithe: (2021-11-01)

Response to Gefitinib in Pericardial Effusion Due to Lung Cancer
de réir: Norihiro Kikuchi, et al.
Foilsithe / Cruthaithe: (2003-01-01)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
de réir: Jun Li, et al.
Foilsithe / Cruthaithe: (2020-02-01)

Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer
de réir: Honggang Wang, et al.
Foilsithe / Cruthaithe: (2017-07-01)

Gefitinib-induced pyogenic granuloma in a patient with lung cancer
de réir: Satyajeet Sahoo, et al.
Foilsithe / Cruthaithe: (2020-01-01)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
de réir: Hongbo Zhao, et al.
Foilsithe / Cruthaithe: (2018-11-01)

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
de réir: T Brown, et al.
Foilsithe / Cruthaithe: (2010-10-01)

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
de réir: Horak, J, et al.
Foilsithe / Cruthaithe: (2011)

Pyogenic Granuloma in a Patient on Gefitinib
de réir: António Fernandes Massa, et al.
Foilsithe / Cruthaithe: (2016-06-01)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
de réir: Tatsuya Nagano, et al.
Foilsithe / Cruthaithe: (2011-01-01)

Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma
de réir: Brown, N, et al.
Foilsithe / Cruthaithe: (2016)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
de réir: Nicholas Brown, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
de réir: Iwao Shimomura, et al.
Foilsithe / Cruthaithe: (2013-01-01)

Design of gefitinib-loaded PLGA microspheres via microfluidics for lung cancer
de réir: Ruohan Huang, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Drug delivery systems of gefitinib for improved cancer therapy: A review
de réir: Deepak Nagdiya, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Gefitinib for Non-small Cell Lung Cancer: A meta Analysis
de réir: Jiwu GUO, et al.
Foilsithe / Cruthaithe: (2011-04-01)

Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
de réir: Yung-Hung Luo, et al.
Foilsithe / Cruthaithe: (2015-09-01)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
de réir: Takuya Araki, et al.
Foilsithe / Cruthaithe: (2013-01-01)

VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION
de réir: Midgley, R, et al.
Foilsithe / Cruthaithe: (2008)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
de réir: Zhonghan Zhang, et al.
Foilsithe / Cruthaithe: (2019-11-01)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib.
Foilsithe / Cruthaithe: (2012-03-01)

Gefitinib: Combination Therapy and Complex Delivery Systems (Review)
de réir: L. L. Nikolaeva, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Cellular photo(geno)toxicity of gefitinib after biotransformation
de réir: Meryem El Ouardi, et al.
Foilsithe / Cruthaithe: (2023-06-01)

The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer
de réir: Puwei Song, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Gefitinib plus chemotherapy for EGFR-mutant non-small-cell lung cancer
de réir: Aman Chaudhary, et al.
Foilsithe / Cruthaithe: (2022-01-01)

FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer
de réir: Jian Li, et al.
Foilsithe / Cruthaithe: (2023-02-01)

PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer
de réir: Sherif AY, et al.
Foilsithe / Cruthaithe: (2022-07-01)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
de réir: Fengqi Xiao, et al.
Foilsithe / Cruthaithe: (2020-11-01)

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
de réir: William Pao, et al.
Foilsithe / Cruthaithe: (2005-01-01)

Anti-Tumor Activity of Orally Administered Gefitinib-Loaded Nanosized Cubosomes against Colon Cancer
de réir: Ahmed A. El-Shenawy, et al.
Foilsithe / Cruthaithe: (2023-02-01)

Development of rheumatoid arthritis during the course of gefitinib therapy
de réir: Gen Ohara, et al.

Not COVID-19, Don’t Overlook Pneumocystis in Patients on Gefitinib!
de réir: Jérémy Barben, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer
de réir: Chi Pan, et al.
Foilsithe / Cruthaithe: (2016-09-01)

Gefitinib Monotherapy in Advanced non-small-cell Lung Cancer: A Retrospective Analysis
de réir: S Shrestha, et al.
Foilsithe / Cruthaithe: (2012-06-01)

The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro
de réir: Zhao Lu-Jun, et al.
Foilsithe / Cruthaithe: (2009-09-01)

Molecular Factors Related to Gefitinib Efficacy in Advanced Non-small Cell Lung Cancer
de réir: Tao ZHOU, et al.
Foilsithe / Cruthaithe: (2010-03-01)